| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ ...
 
																	Item 1.01 Entry into a Material Definitive Agreement On September 9, 2025, Serina Therapeutics, Inc., a Delaware corporation (t...
 
																	Transaction structured to provide flexible funding to support Phase 1b registrational clinical study program in advanced Parkin...
 
																	
 
																	HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Serina Therapeutics (AMEX:SER) with a Buy and maintains $15 pr...
 
																	
 
																	SATS: 92% | EchoStar To Sell 3.45 GHz And 600 MHz Spectrum Licenses To AT&T For $23B, Establishes Hybrid MNO Agreement With...
 
																	
